NASDAQ:SVRASavara Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.44 -0.01 (-0.41 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$2.34Now: $2.44▼$2.4850-Day Range$2.08MA: $2.36▼$2.5652-Week Range$0.69Now: $2.44▼$11.39Volume458,532 shsAverage Volume279,765 shsMarket Capitalization$127.34 millionP/E RatioN/ADividend YieldN/ABeta0.94 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingSavara has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.32, Savara has a potential upside of 241.0% from its current price of $2.44.Amount of Analyst CoverageSavara has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesSavara has received 259 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSavara has received 280 “underperform” votes. (Add your “underperform” vote.)Community SentimentSavara has received 51.95% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote “Outperform” if you believe SVRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Savara insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.77% of the stock of Savara is held by insiders.Percentage Held by Institutions46.02% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Savara are expected to grow in the coming year, from ($1.04) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.47 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CUSIPN/A CIK1160308 Webwww.savarapharma.com Phone512-614-1848Debt Debt-to-Equity Ratio0.28 Current Ratio13.90 Quick Ratio13.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$5.08 per share Price / Cash Flow0.48 Book Value$1.67 per share Price / Book1.46Profitability EPS (Most Recent Fiscal Year)$4.57 Net Income$-78,170,000.00 Net MarginsN/A Return on Equity-53.48% Return on Assets-40.16%Miscellaneous EmployeesN/A Outstanding Shares52,190,000Market Cap$127.34 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:SVRA Rates by TradingView Receive SVRA News and Ratings via Email Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Savara (NASDAQ:SVRA) Frequently Asked Questions How has Savara's stock been impacted by COVID-19 (Coronavirus)? Savara's stock was trading at $2.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SVRA shares have increased by 3.4% and is now trading at $2.44. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Savara? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Savara. When is Savara's next earnings date? Savara is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Savara. How were Savara's earnings last quarter? Savara Inc (NASDAQ:SVRA) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.01. View Savara's earnings history. What price target have analysts set for SVRA? 5 Wall Street analysts have issued twelve-month price targets for Savara's stock. Their forecasts range from $1.00 to $17.00. On average, they expect Savara's stock price to reach $8.32 in the next year. This suggests a possible upside of 241.0% from the stock's current price. View analysts' price targets for Savara. Has Savara been receiving favorable news coverage? News headlines about SVRA stock have trended positive on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Savara earned a news impact score of 2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutSavara. Who are some of Savara's key competitors? Some companies that are related to Savara include NewLink Genetics (NLNK), VBI Vaccines (VBIV), Urogen Pharma (URGN), Emisphere Technologies (EMIS), Xenon Pharmaceuticals (XENE), BioDelivery Sciences International (BDSI), Beyondspring (BYSI), Neoleukin Therapeutics (NLTX), Fulcrum Therapeutics (FULC), DURECT (DRRX), BioSpecifics Technologies (BSTC), Satsuma Pharmaceuticals (STSA), Protagonist Therapeutics (PTGX), Syros Pharmaceuticals (SYRS) and Catalyst Pharmaceuticals (CPRX). View all competitors. What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BIOLINERX LTD/S (BLRX), CEL-SCI (CVM), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), Gilead Sciences (GILD), Myovant Sciences (MYOV), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). Who are Savara's key executives? Savara's management team includes the following people: Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)Taneli Jouhikainen, President, Chief Operating Officer (Age 51)David L. Lowrance, Chief Financial Officer (Age 50)Nevan C. Elam, Independent Director (Age 49)Richard J. Hawkins, Independent Director (Age 68)Joseph S. McCracken Ph.D., Independent Director (Age 64)Matthew Pauls J.D., Independent Director (Age 46)Yuri Pikover, Independent Director (Age 56) What is Savara's stock symbol? Savara trades on the NASDAQ under the ticker symbol "SVRA." Who are Savara's major shareholders? Savara's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.52%), AXA (2.57%), State Street Corp (1.06%), Geode Capital Management LLC (0.92%), Acadian Asset Management LLC (0.43%) and Dupont Capital Management Corp (0.22%). Company insiders that own Savara stock include David A Ramsay, David L Lowrance, Jaakko Taneli Jouhikainen, Richard J Hawkins and Robert N Neville. View institutional ownership trends for Savara. Which institutional investors are selling Savara stock? SVRA stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Deutsche Bank AG, and UBS Group AG. View insider buying and selling activity for Savara. Which institutional investors are buying Savara stock? SVRA stock was bought by a variety of institutional investors in the last quarter, including AXA, Acadian Asset Management LLC, Dupont Capital Management Corp, Geode Capital Management LLC, Intellectus Partners LLC, BlackRock Inc., SG Americas Securities LLC, and Bank of New York Mellon Corp. Company insiders that have bought Savara stock in the last two years include David A Ramsay, and Robert N Neville. View insider buying and selling activity for Savara. How do I buy shares of Savara? Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Savara's stock price today? One share of SVRA stock can currently be purchased for approximately $2.44. How big of a company is Savara? Savara has a market capitalization of $127.34 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis. What is Savara's official website? The official website for Savara is www.savarapharma.com. How can I contact Savara? Savara's mailing address is 900 S. CAPITAL OF TEXAS HIGHWAY SUITE 150, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
